AstraZeneca


The market’s harsh reaction to the Q4 miss seems unreasonable

08/02/24 -"Even though Q4 profitability fell short of the street’s expectations, the 2023 results met the management’s CER guidance. The management’s 2024 outlook was healthy as well. Still, the share price ..."

Pages
67
Language
English
Published on
08/02/24
You may also be interested by these reports :
22/02/24
Hikma’s H2 23 results exceeded the street’s expectations, with Generics being the lead performer. Even the 2024 guidance was largely in line with the ...

20/02/24
Considering the strong operational performance and a meaningful progress for the late-stage pipeline in recent years, we have revised upwards our NAV ...

20/02/24
FY23 CORE EBITDA ahead of consensus by 1%, CORE net profit miss by 4%

19/02/24
Bayer has announced a dividend cut to the legally-required minimum of 4% of AG capital, which translates to a dividend proposal of 11 euro cents ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO